See also this year's filing and all EDGAR filings for this company.
PDF Report 0000874015_2015_Ionis_Pharmaceuticals_INC.pdf
Logs
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 1.1642363942467189, 'aggregate_val': 698029000, 'exp_sum': 322529000, 'exp_to_value': {'LiabilitiesCurrent': 115332000, 'LiabilitiesNoncurrent': 0, 'remainder_Liabilities': 207197000}} |
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 1.1113518197573657, 'aggregate_val': 755315000, 'exp_sum': 357740000, 'exp_to_value': {'LiabilitiesCurrent': 148876000, 'LiabilitiesNoncurrent': 0, 'remainder_Liabilities': 208864000}} |
| info | NetIncome node detected by tax heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'NetIncomeLossAvailableToCommonStockholdersBasic'} |
Graph
Absolute values for 0000874015, Ionis Pharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 836,597,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 88,958,000 |
| 3 | remainder_Assets | 30,254,000 |
| 4 | LiabilitiesCurrent | 115,332,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 582,697,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 21,225,155 |
| 9 | ResearchAndDevelopmentExpense | 0 |
| 10 | remainder_Expenses | 270,696,101 |
| 11 | remainder_Revenues | 258,051,896 |
| 12 | remainder_NetIncome | -3,049,889 |
| 13 | remainder_ComprehensiveNetIncome | -328,744 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 955,809,000 |
| 1 | Liabilities | 698,029,000 |
| 2 | Expenses | 291,921,256 |
| 3 | Revenues | 258,051,896 |
| 4 | StockholdersEquity | 257,780,000 |
| 5 | NetIncome | -36,919,249 |
| 6 | ComprehensiveNetIncome | -37,083,621 |
| 7 | BaseVar | 1,103,594,892 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 0.635 |
| 9 | EconomicCapitalRatio | 2.00 |